Theravance Biopharma (TBPH)
(Real Time Quote from BATS)
$9.03 USD
-0.14 (-1.53%)
Updated Apr 25, 2024 09:41 AM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Income Statements
Fiscal Year end for Theravance Biopharma, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 57 | 51 | 55 | 72 | 73 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 57 | 51 | 55 | 72 | 73 |
Selling & Adminstrative & Depr. & Amort Expenses | 113 | 143 | 313 | 370 | 325 |
Income After Depreciation & Amortization | -56 | -92 | -258 | -298 | -252 |
Non-Operating Income | 9 | 6 | 105 | 56 | 42 |
Interest Expense | 2 | 6 | 47 | 45 | 32 |
Pretax Income | -49 | -93 | -200 | -287 | -242 |
Income Taxes | 6 | 0 | 0 | -9 | -5 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -55 | -93 | -199 | -278 | -236 |
Extras & Discontinued Operations | 0 | 965 | 0 | 0 | 0 |
Net Income (GAAP) | -55 | 872 | -199 | -278 | -236 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -56 | -89 | -252 | -292 | -249 |
Depreciation & Amortization (Cash Flow) | 0 | 3 | 6 | 6 | 3 |
Income After Depreciation & Amortization | -56 | -92 | -258 | -298 | -252 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 55.30 | 73.59 | 69.46 | 62.35 | 55.61 |
Diluted EPS Before Non-Recurring Items | -1.00 | -1.26 | -2.87 | -4.20 | -4.25 |
Diluted Net EPS (GAAP) | -1.00 | 11.85 | -2.87 | -4.46 | -4.25 |
Fiscal Year end for Theravance Biopharma, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 17.57 | 15.69 | 13.75 | 10.42 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 17.57 | 15.69 | 13.75 | 10.42 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 23.80 | 24.45 | 29.88 | 35.33 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -6.23 | -8.76 | -16.13 | -24.91 |
Non-Operating Income | NA | 1.85 | 1.79 | 2.50 | 2.98 |
Interest Expense | NA | 0.62 | 0.61 | 0.57 | 0.55 |
Pretax Income | NA | -5.02 | -7.58 | -14.19 | -22.48 |
Income Taxes | NA | 3.49 | 1.37 | 1.46 | -0.40 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -8.51 | -8.95 | -15.65 | -22.09 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -8.51 | -8.95 | -15.65 | -22.09 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 49.42 | 52.36 | 56.68 | 62.93 |
Diluted EPS Before Non-Recurring Items | NA | -0.17 | -0.17 | -0.28 | -0.32 |
Diluted Net EPS (GAAP) | NA | -0.20 | -0.17 | -0.28 | -0.35 |